Revolo Biotherapeutics
Cambridge
About Revolo Biotherapeutics
Revolo Biotherapeutics has developed therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. Its mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission. Revolo Biotherapeutics was founded in 2011 and formerly known as Immune Regulation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $52.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2020)
- Website: revolobio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/revolo-biotherapeutics-35199 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.